John F. Paolini - 25 Jul 2023 Form 4 Insider Report for Kiniksa Pharmaceuticals, Ltd. (KNSA)

Role
CHIEF MEDICAL OFFICER
Signature
/s/ Madelyn Zeylikman, Attorney-in-Fact
Issuer symbol
KNSA
Transactions as of
25 Jul 2023
Net transactions value
-$501,220
Form type
4
Filing time
27 Jul 2023, 16:30:43 UTC
Previous filing
11 Apr 2023
Next filing
06 Sep 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KNSA Class A Common Share Options Exercise $53,940 +29,000 +69% $1.86* 70,910 25 Jul 2023 Direct F1
transaction KNSA Class A Common Share Sale $93,652 -5,200 -7.3% $18.01 65,710 25 Jul 2023 Direct F1, F2
transaction KNSA Class A Common Share Sale $311,234 -16,168 -25% $19.25 49,542 25 Jul 2023 Direct F1, F3
transaction KNSA Class A Common Share Sale $150,274 -7,632 -15% $19.69 41,910 25 Jul 2023 Direct F1, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KNSA Share Option Options Exercise $0 -29,000 -17% $0.000000 140,217 25 Jul 2023 Class A Common Share 29,000 $1.86 Direct F1, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan executed by the reporting person on August 16, 2022.
F2 This transaction was executed in multiple trades through a broker-dealer at prices ranging from $17.50 to $18.49. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
F3 This transaction was executed in multiple trades through a broker-dealer at prices ranging from $18.50 to $19.49. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
F4 This transaction was executed in multiple trades through a broker-dealer at prices ranging from $19.50 to $19.94. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
F5 The option is fully vested and exercisable.